Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World February 26, 2008 James Mitchell Crow	Q and A: Do Antidepressants Work? A widely-reported analysis of clinical trial data for Prozac and related antidepressant drugs has claimed that the medicines work little better than chemically-inactive placebos in all but the most severely depressed patients.
The Motley Fool August 31, 2009 Brian Orelli	Don't Let Dummy Pills Make You a Dummy Investor Instead of being scared that the sugar pill will perform better than expected, pharma investors should factor it in and require more information before investing in companies with drugs that may be affected by it..
Wired August 24, 2009 Steve Silberman	Placebos Are Getting More Effective. Drugmakers Are Desperate to Know Why. The fact that taking a faux drug can powerfully improve some people's health -- the so-called placebo effect -- has long been considered an embarrassment to the serious practice of pharmacology.
The Motley Fool March 16, 2011 Brian Orelli	Different Name, Same Great Results Incyte and Novartis' ruxolitinib passes another clinical trial.
The Motley Fool September 7, 2007 Brian Orelli	Clinical Data Gets Personal Clinical Data's lead compound Vilazodone posts strong phase 3 results. The company is searching for common genetic markers among patients who responded positively to the drug.
The Motley Fool March 4, 2011 Brian Orelli	Pfizer's Biggest Shot at Lipitor 2.0 It might need a little help from competitors.
The Motley Fool September 6, 2011 Brian Orelli	Better Late Than Never? Maybe. Can Vertex's rheumatoid arthritis drug, VX-509, succeed this late in the game?
Chemistry World September 2007 Derek Lowe	Column: In the Pipeline Will Phase Zero trials actually help drug development?
The Motley Fool March 29, 2010 Brian Orelli	Look for Companies That Strike First Head-to-head trials, whether they're run by companies or by third parties, can be scary. But the way to make big money is by selling drugs that offer superior benefits, so investors should welcome the onslaught of upcoming comparative trial data.
The Motley Fool September 8, 2010 Brian Orelli	You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win.
The Motley Fool March 3, 2010 Brian Orelli	A Costly Missed Connection Dimebon's phase 3 failure costs Medivation shareholders 67%.
Chemistry World September 2009	Column: In the pipeline What's the most difficult therapeutic area for drug discovery? They're certainly not all created equal - or if they were, they have definitely diverged since then. The question can be narrowed down quite a bit.
The Motley Fool February 11, 2010 Brian Orelli	A Wonder Drug With Not-So-Wonderful Side Effects Wonder drug or not, Isis Pharmaceuticals and Genzyme's cholesterol drug mipomersen's sales will be limited by side effects.
The Motley Fool June 3, 2011 Brian Orelli	FDA Bullies Obesity Drugmakers It's been clear for some time that the Food and Drug Administration isn't particularly fond of obesity drugs. Now it's just being a bully.
The Motley Fool January 29, 2010 Brian Orelli	How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years.
The Motley Fool January 3, 2011 Brian Orelli	Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure.
Chemistry World April 12, 2011 Meera Senthilingam	How antidepressants spur brain growth Researchers have identified the mechanism by which some antidepressants stimulate the formation of new brain cells, an insight that could lead to improved drugs.
The Motley Fool August 31, 2010 Brian Orelli	Drugmakers May Lose a Back Door for Drug Approval Non-inferiority trials may be inferior.
The Motley Fool December 9, 2010 Brian Orelli	Here Comes Another Oral MS Drug Good for Teva, bad for the rest.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
Chemistry World March 2011	Column: In the pipeline Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations
The Motley Fool March 31, 2011 Brian Orelli	Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones?
The Motley Fool December 15, 2010 Brian Orelli	Beautiful Efficacy, Wrong Pill Lexicon Pharmaceuticals presented beautiful data showing a pill it gave rheumatoid arthritis patients decreased symptoms in 49% of patients. Unfortunately, the pill was a dummy pill with no active ingredient.
IEEE Spectrum March 2006 Samuel K. Moore	Psychiatry's Shocking New Tools Electronic implants and electromagnetic pulses are picking up where psychoactive drugs have failed.
The Motley Fool May 11, 2010 Ryan McBride	Clinical Data Seeks to Challenge Lilly, Pfizer in Antidepressant Market The tiny drug developer has no problem going up against bigger rivals.
The Motley Fool January 25, 2011 Brian Orelli	FDA Approved -- Now Will It Sell? There's still plenty of uncertainty in Clinical Data's shares.
IEEE Spectrum March 2011 Samuel K. Moore	Teaching Machines About Madness Software rivals doctors at distinguishing among different kinds of depression and schizophrenia
The Motley Fool September 7, 2010 Luke Timmerman	Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too.
Reason October 2005 Maia Szalavitz	In Defense of Happy Pills While psychotherapy validated by research has its place, there is no convincing reason why it should be considered inherently superior to drugs. Pleasure can be just as important for emotional recovery and growth as pain, if not more so.
Salon.com July 11, 2001 Amy Benfer	A history of failure Author and psychologist Bruce Levine pummels psychiatry, psychotropic drugs and the role both may have played in the case of Andrea Yates...
The Motley Fool September 14, 2010 Luke Timmerman	Arena Obesity Drug Effective by "Slim Margin"; Shares Tumble The market is reacting negatively to news about the company's weight-loss drug.
The Motley Fool August 30, 2010 Brian Orelli	Pipeline Checkup: Merck Has Potential The Schering-Plough acquisition has seemed to help.
BusinessWeek April 26, 2004 Carol Marie Cropper	A Cloud Over Antidepressants Do some popular drugs cause suicidal behavior in teens?
The Motley Fool March 31, 2009 Brian Orelli	Pharma's Refreshing Bad News Schering-Plough and Eli Lilly both present data at scientific meetings over the weekend about drugs that failed their clinical trials, but it's not bad news.
The Motley Fool June 9, 2010 Brian Orelli	The Drug Passed, but the Stock Fell? Regeneron only bats .500.
The Motley Fool June 10, 2011 Brian Orelli	Abbott Picks Pumps Over Pills Treat Parkinson's disease, medical-device style.
Chemistry World July 3, 2014 Maria Burke	Renewed focus on dementia checked by drug challenges The risks and barriers for companies working in dementia are huge, but so too, potentially, are the rewards, says Simon Ridley, head of research at Alzheimer's Research UK.
Nurse Practitioner October 2011 Krauter & Cook	Pharmacogenetics and the pharmacological management of depression One CYP450 enzyme, CYP2D6, is responsible for the metabolism of 30% of all drugs including many antidepressants. Phenotypes of metabolizer status affect antidepressant treatment outcomes and adverse drug reactions.
ifeminists November 17, 2004 Byron Fraser	Review: Your Drug May Be Your Problem Excerpts from the book Your Drug May Be Your Problem: How and Why to Stop Taking Psychiatric Medications by Peter Breggin and David Cohen delineating the adverse effects of these medications and how to stop taking them.
The Motley Fool April 25, 2011 Luke Timmerman	Vertex, Merck Step Up to the Public Stage With Hepatitis C Drugs This Week Most analysts see Vertex's drug as best-in-class. But what does the FDA have to say about it?
The Motley Fool June 25, 2010 Brian Orelli	Mark Your Calendars: Obesity Drugs Take Center Stage Orexigen Therapeutics has been given an FDA advisory committee meeting date, completing the dates for the trio of obesity drugs up for review.
The Motley Fool May 17, 2010 Luke Timmerman	Vertex Awaits Final Proof that Hepatitis C Drug Works For this drug researcher, the proof is in the telaprevir.
Bio-IT World March 2006 Kevin Davies	Clinical Data Launches Landmark Trial Clinical Data has launched a Phase III clinical trial for the depression drug vilazodone and will concurrently develop a diagnostic test. The study could prove to be a landmark event in pharmacogenomic medicine.
The Motley Fool June 6, 2011 Luke Timmerman	Exelixis Zeroes In on Lead Drug, Sees Activity in the Bones of Prostate Cancer Patients Is Exelixis' risky bet about to pay off?
Chemistry World October 3, 2006 Victoria Gill	Ten Year Setback for Obesity Control The race for an effective appetite-suppressing, anti-obesity drug has been held back by disappointing results from a human clinical trial. The findings underline the complexity of human obesity, conclude the researchers, and suggest it could be many years before a drug gets to market.
The Motley Fool March 25, 2011 Brian Orelli	Pfile Pfizer Under "Potential" Researchers reported promising finding from a clinical trial of Pfizer's new drug, CP-870,893, in pancreatic cancer patients in the most recent issue of the journal Science.
The Motley Fool July 30, 2010 Brian Orelli	3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company.
The Motley Fool February 22, 2011 Ryan McBride	Forest Labs Snaps Up Clinical Data This deal is the latest proof that drug developers with FDA-approved treatments remain hot buyout targets in a pharma industry that is starved for new products to replace brand-name drugs.
The Motley Fool April 2, 2007 Brian Lawler	A Good Week for Alexza The pharma reports positive clinical trial results. Investors, take note.
Chemistry World October 8, 2010 Sarah Houlton	U-turn on Alzheimer's drugs in the UK The UK National Institute for Health and Clinical Excellence proposes that those with mild disease will be able to receive them from early next year, on the basis of growing clinical evidence of their effectiveness.